指南与共识系统性红斑狼疮

系统性红斑狼疮缓解定义框架:DORIS 国际工作组共识

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
指南 / 共识 · Ann Rheum Dis · 2016-11-24

国际工作组由60名专家和患者代表参与,通过准备练习、面对面会议和电子投票,以90%同意水平就SLE缓解定义达成八项关键声明和三项指导原则。缓解被定义为基于症状、体征和常规实验室检查的持久状态,需使用验证性指数评估,并区分停药缓解与用药缓解。工作组还确定了用于检验缓解定义预后价值的结局指标。

要点

  • SLE缓解应定义为基于症状、体征和常规实验室检查的持久状态。
  • 评估缓解需使用验证性指数如临床SLEDAI=0、BILAG 2004仅D/E或临床ECLAM=0,并辅以医生整体评估。
  • 区分停药缓解(仅用抗疟药维持)与用药缓解(允许稳定维持抗疟药、泼尼松≤5 mg/天、免疫抑制剂和/或生物制剂)。

核心结论

  • 国际工作组就SLE缓解定义达成共识框架,为测试不同缓解定义与长期结局的关系提供基础。

研究设计与样本

  • 国际工作组由60名专家和患者代表参与,通过准备练习、面对面会议和后续电子投票达成共识,同意水平设定为90%。

主要发现

  • 工作组就SLE缓解达成八项关键声明和三项指导原则。
  • 缓解定义需参考症状、体征和常规实验室检查,并应使用验证性指数评估。
  • 工作组确定死亡、损伤、复发和健康相关生活质量指标为检验缓解定义预后价值的最合适结局。

关键数值与推荐

  • 缓解定义应使用验证性指数,例如临床SLEDAI=0、BILAG 2004仅D/E或临床ECLAM=0,并包括常规实验室评估和医生整体评估。
  • 停药缓解要求患者除维持抗疟药外不接收其他SLE治疗。
  • 用药缓解允许患者使用稳定维持抗疟药、低剂量糖皮质激素(泼尼松≤5 mg/天)、维持免疫抑制剂和/或维持生物制剂。
  • 共识同意水平设定为90%。

临床怎么用

  • 临床评估SLE缓解时应基于症状、体征和常规实验室检查,使用验证性指数如临床SLEDAI=0、BILAG 2004仅D/E或临床ECLAM=0,并辅以医生整体评估。
  • 区分停药缓解与用药缓解,根据患者是否仅用维持抗疟药或允许使用低剂量糖皮质激素、免疫抑制剂和/或生物制剂进行判断。

局限性

  • 原文未报告共识框架的具体验证结果或长期结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. METHODS: An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. RESULTS: The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. CONCLUSIONS: The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2016. PMID: 27884822. doi:10.1136/annrheumdis-2016-209519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。